Monoclonal antibody · Antagonist of interleukin-23 subunit alpha (p19) (IL23A) · developed by Janssen Biotech
Guselkumab is a human IgG1 lambda monoclonal antibody that selectively binds the p19 subunit of interleukin-23 and blocks its interaction with the IL-23 receptor, reducing release of proinflammatory cytokines and chemokines.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 4, 2026). Read the full label for the exact wording, limitations and safety information.
Arthritis, Psoriatic
Updated Oct 18, 2026. Something wrong or missing? Report it on the JNJ page.
See JNJ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JNJ catalysts and pipeline →